MediaAlpha, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This is an annual filing, not a standalone fourth-quarter report; the supplied filing text does not provide a clear set of Q4-only financial results.
Business context
MediaAlpha operates a technology-enabled marketplace connecting insurance carriers and distributors with high-intent consumers. It earns fees when consumer clicks, calls, or leads are transacted. Insurance accounted for 96.6% of revenue. The company reported $593.4 million of total Transaction Value across its platform; P&C, health, and life insurance together represented approximately $571.4 million.
Financial and operating performance
| Metric | FY2023 | FY2022 | Change |
|---|---|---|---|
| Revenue | $388.1 million | $459.1 million | Down 15.4% |
| Transaction Value | $593.4 million | $737.5 million | Down 19.5% |
| Gross profit / gross margin | $66.7 million / 17.2% | $70.1 million / 15.3% | Margin up 1.9 percentage points |
| Contribution / Contribution Margin (non-GAAP) | $78.1 million / 20.1% | $80.8 million / 17.6% | Contribution down 3.3%; margin up 2.5 points |
| Operating loss | $39.9 million | $35.4 million | Loss widened |
| Net loss | $56.6 million | $72.4 million | Loss narrowed |
| Net loss attributable to MediaAlpha, Inc. / diluted EPS | $40.4 million / $(0.89) | $57.7 million / $(1.37) | Loss per share narrowed |
| Adjusted EBITDA (non-GAAP) | $27.1 million | $22.9 million | Up 18.6% |
| Cash from operating activities | $20.2 million | $28.3 million | Down 28.4% |
Revenue by vertical: P&C $164.2 million (down 26.8%); health $186.3 million (down 0.6%); life $24.3 million (down 9.1%); other $13.4 million (down 35.2%). Consumer Referrals purchased by insurance buyers increased to 98.8 million from 90.4 million, despite lower Transaction Value.
At year-end, cash and cash equivalents were $17.3 million, versus $14.5 million a year earlier. Debt principal outstanding was $176.0 million, comprising a $171.0 million term loan and $5.0 million revolver borrowing; $45.0 million of revolving capacity remained available. Debt carrying value, net of issuance costs, was $174.3 million. The reported interest rate was 8.20%, and interest expense was $15.3 million, versus $9.2 million in 2022. The company was in compliance with its financial covenants at December 31, 2023; facilities mature July 29, 2026.
Changes, outlook, and material matters
- Management attributed the revenue and Transaction Value declines primarily to reduced P&C carrier customer-acquisition spending amid elevated claims costs and weak underwriting profitability. It said carrier profitability began improving late in 2023 as premium increases outpaced loss-cost inflation.
- Management expects P&C customer-acquisition spending and revenue to improve during 2024, potentially beginning in Q1, but said it cannot reliably predict the recovery’s timing or impact beyond Q1 2024. This is a qualitative outlook, not quantified formal guidance.
- Health performance included strength in under-65 insurance, offset by lower Medicare referral supply amid partners’ challenges adapting to marketing-rule changes. Life revenue also declined, while higher publisher acquisition costs reduced travel referrals.
- Adjusted EBITDA increased largely due to lower personnel costs following a May 2023 reduction in force and lower directors’ and officers’ insurance premiums. The reduction in force generated $1.2 million of severance costs.
- Comparability of net loss is affected by 2022 items: a $83.3 million gain from reducing the Tax Receivables Agreement liability and $102.9 million of income tax expense, primarily associated with a valuation allowance on deferred tax assets. The 2023 results included a $1.4 million impairment of a cost-method investment and higher interest expense.
- The company received an FTC civil investigative demand in February 2023 concerning healthcare-related marketing, consumer data, telemarketing, privacy, and data security. It is cooperating; the outcome and potential significance are uncertain. It incurred $3.9 million of legal fees related to the demand and reported no material contingency reserve for the matter.
- Key risks include the cyclical and concentrated nature of insurance customer-acquisition spending, reliance on partners that generally have no minimum-volume commitments, variable-rate debt and covenant sensitivity, evolving insurance and privacy rules, and cybersecurity and platform availability. The company also disclosed that its deferred tax assets are fully offset by a valuation allowance and that it does not expect TRA payments to be probable in the foreseeable future.
- Management said available liquidity should cover operating and debt-service needs for at least 12 months, while cautioning that a weaker-than-expected recovery could require cost reductions, covenant relief, refinancing, or additional capital. No cash dividends are expected in the foreseeable future.
Investor facts to verify
- Track P&C carrier rate adequacy, underwriting profitability, and actual advertising-spend recovery against management’s uncertain 2024 outlook.
- Monitor operating cash generation, available revolver capacity, debt service, and compliance with credit-facility covenants.
- Follow the FTC inquiry, evolving Medicare marketing and telemarketing consent rules, and any resulting business or compliance changes.
- Assess whether lower revenue can be offset by Contribution Margin and cost discipline, while noting that Adjusted EBITDA is non-GAAP and excludes substantial items, including equity-based compensation.
- Review partner and supplier concentration, referral quality and volume, and the ability to sustain health and life performance as P&C conditions evolve.
The independent auditor issued an unqualified opinion on the financial statements and internal control over financial reporting; management and the auditor reported effective internal controls as of December 31, 2023.